


## PD146176

Cat. No.:	HY-103157		
CAS No.:	4079-26-9		
Molecular Formula:	C <sub>15</sub> H <sub>11</sub> NS		
Molecular Weight:	237		
Target:	Autophagy; Ferroptosis		
Pathway:	Autophagy; Apoptosis		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (105.49 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
			1 mM	4.2194 mL	21.0970 mL	42.1941 mL
			5 mM	0.8439 mL	4.2194 mL	8.4388 mL
			10 mM	0.4219 mL	2.1097 mL	4.2194 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (10.55 mM); Suspended solution; Need ultrasonic					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (10.55 mM); Suspended solution; Need ultrasonic					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (10.55 mM); Clear solution					

### BIOLOGICAL ACTIVITY

Description	PD146176 (NSC168807), a 15-Lipoxygenase (15-LO) inhibitor, inhibits rabbit reticulocyte 15-LO (K <sub>i</sub> =197 nM, IC <sub>50</sub> =0.54 μM). PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice <sup>[1][2][3]</sup> .
IC <sub>50</sub> & Target	Ki: 197 nM (Rabbit reticulocyte 15-LO) <sup>[1]</sup> IC50: 0.54 μM <sup>[2]</sup>
In Vitro	In intact IC21 cells transfected with human 15-LO, PD146176 inhibits 13-HODE production with an IC <sub>50</sub> of 0.81 μM <sup>[2]</sup> .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

PD146176 (80 mg/kg; Chowing; 12 weeks) reverses cognitive impairment, brain amyloidosis, and Tau pathology by stimulating autophagy in aged triple transgenic mice<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Triple transgenic (3xTg) mice <sup>[3]</sup>
Dosage:	80 mg/kg
Administration:	Chowing; 12 weeks
Result:	Significantly lower amyloid beta levels and deposition, less tau neuropathology, increased synaptic integrity, and autophagy activation.

## CUSTOMER VALIDATION

- Biosci Trends. 2022 Aug 7.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Sendobry SM, et al. Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. *Br J Pharmacol.* 1997;120(7):1199-1206.
- [2]. Bocan TM, et al. A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit [published correction appears in *Atherosclerosis* 1998 Jul;139(1):201]. *Atherosclerosis.* 1998;136(2):203-216.
- [3]. Di Meco A, et al. 12/15-Lipoxygenase Inhibition Reverses Cognitive Impairment, Brain Amyloidosis, and Tau Pathology by Stimulating Autophagy in Aged Triple Transgenic Mice. *Biol Psychiatry.* 2017;81(2):92-100.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA